-
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational ...
-
The Phase I study (HPTN 050) is sponsored by the Division of AIDS of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and is being conducted by the ...
-
Gilead Sciences Provides Update on PREVEON® Clinical Program for the Treatment of HIV
PREVEON Profile to be Highlighted in Five Oral Presentations at ICAAC ConferenceFoster City, CA -- September 23, 1998Gilead Sciences, Inc. (Nasdaq: GILD) announced today the completion of enrollment in ...
-
-- U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19 -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 26, 2020-- Gilead Sciences, Inc. (Nasdaq: ...
-
-- Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States -- -- Veklury Shortened Time to Recovery By Five Days in Hospitalized COVID-19 Patients -- ...
-
-- Data Presented Includes a Comparative Analysis of Clinical Recovery and Mortality Outcomes from the Phase 3 SIMPLE Trial Versus Real-World Cohort of Severe COVID-19 Patients Receiving Standard ...
-
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- In the weeks since we learned of remdesivir’s potential against COVID-19, one topic has attracted more speculation than any other: what price we might ...
-
-- Veklury is Currently Available in the U.S. for the Treatment of Severe COVID-19 Under an Emergency Use Authorization -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: ...
-
-- Expands Previous Authorization of Veklury to Treat Hospitalized Patients with COVID-19 Regardless of Oxygen Status -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: ...
-
-- Remdesivir treatment resulted in clinical improvement in 68 percent of patients in this limited data set -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) ...